Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Agilent Technologies (A) stock in plain English

Free brief · no signupStart here
APublished Nov 9, 2026
Agilent Technologies Inc
Healthcare · Diagnostics & Research
Produces chromatographs, mass spectrometers, and pathology equipment for research and clinical laboratories.
Assets:
18,000 employeesStaff across manufacturing, research, and support hubs globally
Global manufacturing networkKey production sites operating across the United States, Europe, and Asia
Dako pathology lineCancer diagnostic stains and automated tissue-processing instruments
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

64
OPS ScoreOperating finances
Latest quote
-1.12%$175.34
$49.43B
34.5×
$7.37B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 09, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was A. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Agilent Technologies (A) do?

Agilent Technologies Inc (A) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Produces chromatographs, mass spectrometers, and pathology equipment for research and clinical laboratories. Makes analytical instruments and diagnostic tools that laboratories use to identify chemical compounds and biological. It is worth $49.43B on the market and sold $7.37B over the last year.

Market cap
$49.43B
P/E ratio
34.5×
Annual sales
$7.37B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 09, 2026

Brands and businesses behind A

  • Dako: Supplies antibodies, reagents, and automated tissue-staining instruments to hospital labs for cancer diagnosis.
  • BioTek: Builds microplate readers, washers, and imaging systems used in cellular analysis and pharmaceutical screening.

A’s flags, in plain English

Each flag is a number from Agilent Technologies’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 09, 2026.

Stupid Cash

Can pay this year's bills 2.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 54% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 19.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Priced for Perfection

Priced at 34.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about A

How big is Agilent Technologies?

Agilent Technologies’ market cap is $49.43B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $7.37B: what customers paid the company over the last year, before any costs.

What is A’s P/E ratio?

A’s P/E ratio is 34.5×. Investors pay about 34.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with A?

Reduced research budgets across biotech and pharmaceutical companies directly depress demand for new lab equipment. That is one risk on Agilent Technologies’ card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Agilent Technologies’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. A’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card